Biotech

All Articles

Bicara, Zenas find IPOs to drive late-phase resources toward market

.Bicara Rehabs and also Zenas Biopharma have actually given fresh impetus to the IPO market along wi...

Genentech to shut cancer immunology research team

.Genentech is going to close its cancer immunology analysis department, and unit mind as well as ren...

Kezar falls strong tumor however to show its really worth in phase 1 trial

.Kezar Life Sciences is dropping its own unpromising period 1 strong growth medicine as the biotech ...

Acelyrin loses izokibep, lets go 3rd of workers

.In spite of izokibep keeping its newly found winning touch in the medical clinic, Acelyrin is no lo...

Rivus' phase 2 obesity-related cardiac arrest trial attacks endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its fat-busting, muscle-sparing medication ap...

Ovid stops preclinical job, IV plan after soticlestat fall short

.Ovid Rehab presently revealed last month that it was actually trimming its head count as the compan...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston Seaport

.Eli Lilly has actually opened a $700 thousand R&ampD facility in the Boston ma Seaport, improving i...

Boundless Biography creates 'reasonable' layoffs 5 months after $100M IPO

.Merely five months after protecting a $one hundred million IPO, Boundless Biography is already layi...

Halda's $126M will definitely advance 'secure and get rid of' tumor medications

.The first stages of oncology R&ampD may not be short of interesting brand-new techniques, and also ...

Lykos 'remorses' certainly not making known study infractions with publisher

.Psychopharmacology has actually drawn three short articles concerning midstage clinical trial recor...